Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 9INDUSTRY 5NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colonic Neoplasms 226Colorectal Neoplasms 203Rectal Neoplasms 194Pancreatic Neoplasms 158Carcinoma, Hepatocellular 109Stomach Neoplasms 94Esophageal Neoplasms 81Liver Neoplasms 72Breast Neoplasms 68Lung Neoplasms 53Neoplasms 48Carcinoma, Non-Small-Cell Lung 47Neoplasm Metastasis 46Ovarian Neoplasms 44Sarcoma 43Bile Duct Neoplasms 38Gallbladder Neoplasms 37Melanoma 33Anus Neoplasms 31Prostatic Neoplasms 30Adenocarcinoma Of Esophagus 29Lymphoma, Non-Hodgkin 28Carcinoma, Renal Cell 28Uterine Cervical Neoplasms 27Osteosarcoma 27Gastrointestinal Stromal Tumors 27Gastrointestinal Neoplasms 27Neuroectodermal Tumors, Primitive, Peripheral 25Neuroblastoma 25Wilms Tumor 24

Interventions

adavosertib 1Gemcitabine 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Pancreatic Adenocarcinoma × Gastrointestinal × Clear all
NCT02194829 2023-04-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Completed
8 enrolled 9 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡